Ultra-Low Dose PCV2 Antigen Vaccine Overcomes Maternal Antibody Interference
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines for porcine circovirus type 2 (PCV2) are ineffective in young piglets due to maternal antibodies, which interfere with the immune response, and there is a lack of effective solutions for reducing clinical symptoms and infections in animals with anti-PCV2 antibodies.
Innovation Solution
Administration of an immunogenic composition containing PCV2 antigen, specifically the ORF-2 protein, which stimulates an immune response and provides protection against PCV2 infections, even in the presence of maternal antibodies, using a subunit immunogenic composition that includes recombinant baculovirus-expressed PCV2 ORF-2 protein.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional PCV2 vaccines are administered to young piglets, then the vaccine structure is simple and easy to administer, but the maternal antibodies interfere with the immune response rendering the vaccine ineffective
Solution Approach 1:
The patent changes the antigen concentration parameter to ultra-low levels (0.001-1 µg/ml), which is a significant deviation from conventional vaccine concentrations. This parameter change allows the vaccine to be effective in the presence of maternal antibodies by avoiding overwhelming the immune system with high antigen loads that trigger antibody interference, while still providing sufficient antigen to stimulate protective immunity.
2Reliability
If high antigen concentration is used in PCV2 vaccines, then the immune response should be stronger, but the maternal antibodies block the immune response making the treatment ineffective
Solution Approach 1:
The patent applies parameter changes by reducing the antigen concentration to ultra-low levels (0.001-1 µg/ml). This counterintuitive reduction in antigen quantity overcomes the blocking effect of maternal antibodies while still eliciting sufficient immune response, demonstrating that less antigen can be more effective in the presence of pre-existing antibodies.
3Reliability
If vaccination is delayed until maternal antibodies decay, then the vaccine becomes effective, but the piglets remain vulnerable to PCV2 infection during the vulnerable period
Solution Approach 1:
The patent applies preliminary action by administering the ultra-low concentration vaccine immediately to newborn piglets before maternal antibodies fully decay. This early intervention provides continuous protective coverage without interruption, eliminating the vulnerable period while the vaccine works effectively despite the presence of maternal antibodies.
4Reliability
If conventional vaccine doses are administered, then the antigen load is sufficient to induce immunity, but the maternal antibodies neutralize the antigen preventing immune response
Solution Approach 1:
The patent changes the concentration parameter to ultra-low levels and maintains a simple formulation without complex adjuvants or delivery systems. This simplicity, combined with the optimized concentration parameter, allows the vaccine to effectively induce protective immunity in the presence of maternal antibodies without requiring complex formulation strategies.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The immunogenic composition effectively reduces the severity and incidence of PCV2-associated clinical symptoms and infections in young animals and those with maternal antibodies, shortening the duration of viremia, reducing viral load, and enhancing immune resistance.
Implementation Method 1
Administration of an immunogenic composition containing PCV2 antigen, specifically the ORF-2 protein, which stimulates an immune response and provides protection against PCV2 infections
Data Source
AI summary
The present invention relates to a method for the treatment or prophylaxis of a PCV2 infection or for reduction of clinical symptoms caused by or associated with a PCV2 infection in animals a) having anti-PCV2 antibodies and/or b) being young piglets of 1 to 22 days of age, comprising the step of administering an effective amount of a PCV2 antigen to that animal in need of such treatment. Preferably, those animals are pigs or young piglets.